Research ExplorerPublicationsRecommendations to Balance Benefits and Risks Of Thromboprop...

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

Standard

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. / Fankhauser, Christian Daniel; Oldenburg, Jan; Albers, Peter; Algaba, Ferran; Bokemeyer, Carsten; Boormans, Joost L; Fischer, Stefanie; Fizazi, Karim; Gremmels, Hendrik; Mayor de Castro, Javier; Janisch, Florian; Muilwijk, Tim; Leão, Ricardo; Nicol, David; Nicolai, Nicola; Tandstad, Torgrim; Pilar Laguna, M.

In: EUR UROL, Vol. 80, No. 1, 07.2021, p. 4-6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Fankhauser, CD, Oldenburg, J, Albers, P, Algaba, F, Bokemeyer, C, Boormans, JL, Fischer, S, Fizazi, K, Gremmels, H, Mayor de Castro, J, Janisch, F, Muilwijk, T, Leão, R, Nicol, D, Nicolai, N, Tandstad, T & Pilar Laguna, M 2021, 'Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021', EUR UROL, vol. 80, no. 1, pp. 4-6. https://doi.org/10.1016/j.eururo.2021.02.032

APA

Fankhauser, C. D., Oldenburg, J., Albers, P., Algaba, F., Bokemeyer, C., Boormans, J. L., Fischer, S., Fizazi, K., Gremmels, H., Mayor de Castro, J., Janisch, F., Muilwijk, T., Leão, R., Nicol, D., Nicolai, N., Tandstad, T., & Pilar Laguna, M. (2021). Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. EUR UROL, 80(1), 4-6. https://doi.org/10.1016/j.eururo.2021.02.032

Vancouver

Fankhauser CD, Oldenburg J, Albers P, Algaba F, Bokemeyer C, Boormans JL et al. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. EUR UROL. 2021 Jul;80(1):4-6. https://doi.org/10.1016/j.eururo.2021.02.032

Bibtex

@article{f60cbf6425f949559d546f1b9ec731f8,
title = "Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021",
abstract = "Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.",
author = "Fankhauser, {Christian Daniel} and Jan Oldenburg and Peter Albers and Ferran Algaba and Carsten Bokemeyer and Boormans, {Joost L} and Stefanie Fischer and Karim Fizazi and Hendrik Gremmels and {Mayor de Castro}, Javier and Florian Janisch and Tim Muilwijk and Ricardo Le{\~a}o and David Nicol and Nicola Nicolai and Torgrim Tandstad and {Pilar Laguna}, M",
note = "Copyright {\textcopyright} 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2021",
month = jul,
doi = "10.1016/j.eururo.2021.02.032",
language = "English",
volume = "80",
pages = "4--6",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

AU - Fankhauser, Christian Daniel

AU - Oldenburg, Jan

AU - Albers, Peter

AU - Algaba, Ferran

AU - Bokemeyer, Carsten

AU - Boormans, Joost L

AU - Fischer, Stefanie

AU - Fizazi, Karim

AU - Gremmels, Hendrik

AU - Mayor de Castro, Javier

AU - Janisch, Florian

AU - Muilwijk, Tim

AU - Leão, Ricardo

AU - Nicol, David

AU - Nicolai, Nicola

AU - Tandstad, Torgrim

AU - Pilar Laguna, M

N1 - Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2021/7

Y1 - 2021/7

N2 - Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.

AB - Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.

U2 - 10.1016/j.eururo.2021.02.032

DO - 10.1016/j.eururo.2021.02.032

M3 - SCORING: Journal article

C2 - 33722419

VL - 80

SP - 4

EP - 6

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 1

ER -